| Title: |
New 2030 Global Targets for Histoplasmosis from International Society for Human and Animal Mycology (ISHAM) 2025 Histoplasmosis Working Group |
| Authors: |
Pasqualotto,Alessandro C; Denning,David W; Govender,Nelesh P; Hagen, Ferry; Zancope-Oliveira,Rosely M; Caceres,Diego H; Francoise,Ugo; Guimaraes,Allan; Damasceno,Lisandra S; Falci,Diego R; Gomez,Beatriz L; Schwartz,Ilan; Vidal,Jose E; Galan,Luis E; Xavier,Melissa O; Nacher,Mathieu; Effron,Guillermo G; Brown,Gordon; Barros,Nicolas; Godoy,Cassia M; Fraga,Taiguara; Soares,Renata B A; Severo,Cecilia B; Schwarzbold,Alexandre V; Berrio,Indira; de Melo,Marineide G; Reis,Nicole; Tenorio,Bernardo G; Leitao,Terezinha M J; Bastos,Claudilson J de C; Bay,Monica B; de Lacerda,Marcus V G; Bazana,Luana C G; Lana,Daiane F Dalla; Vieceli,Tarsila; Riche,Cezar V W; Arathoon,Eduardo; Canteros,Cristina; Boulware,David; Alastruey-Izquierdo,Ana; Oladele,Rita; Teixeira,Marcus de M; Colombo,Arnaldo L; Perez,Freddy M; Chiller,Tom; Bahr,Nathan C; Tudela,Juan L R; Adenis,Antoine; MMB Medische Staf; Infection & Immunity |
| Publication Year: |
2026 |
| Subject Terms: |
Histoplasmosis/diagnosis; Humans; Animals; Histoplasma; Global Health; Antifungal Agents/therapeutic use; Journal Article |
| Description: |
Histoplasmosis remains a neglected yet deadly fungal infection, disproportionately affecting persons living with HIV/AIDS and other immunocompromised populations in endemic regions. Despite the World Health Organization's designation of Histoplasma as a high-priority pathogen, the disease remains underdiagnosed and excluded from national surveillance systems, resulting in delayed treatment and high death rates. To coordinate a global response, the International Society for Human and Animal Mycology convened a Histoplasmosis Working Group during its 2025 congress in Brazil. Experts engaged in structured discussions across 5 domains: awareness, research, diagnostics and treatment, capacity building, and fungal biology. The group highlighted persistent diagnostic delays, underuse of antigen testing, and poor access to liposomal amphotericin B and itraconazole. Innovations such as lateral flow assays and molecular tools were discussed, alongside the need for biobanks and validated diagnostic algorithms. A global 90-90-90 target for histoplasmosis by 2030 was proposed to improve diagnosis, treatment, and survival. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| ISSN: |
1080-6040 |
| Relation: |
https://dspace.library.uu.nl/handle/1874/469644 |
| Availability: |
https://dspace.library.uu.nl/handle/1874/469644 |
| Rights: |
info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.AC8DABE7 |
| Database: |
BASE |